[go: up one dir, main page]

PT2049148T - Formulação líquida estável da hormona do crescimento humana - Google Patents

Formulação líquida estável da hormona do crescimento humana

Info

Publication number
PT2049148T
PT2049148T PT67691865T PT06769186T PT2049148T PT 2049148 T PT2049148 T PT 2049148T PT 67691865 T PT67691865 T PT 67691865T PT 06769186 T PT06769186 T PT 06769186T PT 2049148 T PT2049148 T PT 2049148T
Authority
PT
Portugal
Prior art keywords
growth hormone
liquid formulation
human growth
stable liquid
stable
Prior art date
Application number
PT67691865T
Other languages
English (en)
Inventor
Hee Kim Sun
Kyung Chung Yo
Young Chang Jae
Sang Kil Lee
Min Suk Lee
Kook Park Seung
Original Assignee
Daewoong Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Co Ltd filed Critical Daewoong Co Ltd
Publication of PT2049148T publication Critical patent/PT2049148T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT67691865T 2006-07-06 2006-07-06 Formulação líquida estável da hormona do crescimento humana PT2049148T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2006/002640 WO2008004717A1 (en) 2006-07-06 2006-07-06 A stable liquid formulation of human growth hormone

Publications (1)

Publication Number Publication Date
PT2049148T true PT2049148T (pt) 2016-12-30

Family

ID=38894670

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67691865T PT2049148T (pt) 2006-07-06 2006-07-06 Formulação líquida estável da hormona do crescimento humana

Country Status (11)

Country Link
US (1) US8409586B2 (pt)
EP (1) EP2049148B1 (pt)
JP (1) JP5180202B2 (pt)
CN (1) CN101505789A (pt)
BR (1) BRPI0621841B8 (pt)
ES (1) ES2605022T3 (pt)
HK (1) HK1216992A1 (pt)
HU (1) HUE031329T2 (pt)
LT (1) LT2049148T (pt)
PT (1) PT2049148T (pt)
WO (1) WO2008004717A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc eMIPを有効成分とする水溶性製剤
CN102665691B (zh) * 2009-11-17 2015-05-27 益普生制药股份有限公司 hGH和rhIGF-1组合的制剂
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
KR101699677B1 (ko) * 2013-11-12 2017-01-24 카딜라 핼쓰캐어 리미티드 고나도트로핀을 위한 제제
US9908976B2 (en) 2015-03-18 2018-03-06 Psmg, Llc Stable polyethylene glycol particle dispersions and methods for forming the stable dispersions
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61296598A (ja) 1985-06-21 1986-12-27 Mitsubishi Electric Corp Mosダイナミツクramのダミ−ワ−ド線駆動回路
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE69334134T2 (de) 1992-07-31 2007-12-20 Genentech, Inc., South San Francisco Wässrige Formulierung enthaltend Menschliches Wachstumshormon
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
KR970006498A (ko) 1995-07-31 1997-02-21 유충식 활성형 인성장호르몬의 정제 방법
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
KR100210840B1 (ko) 1996-12-24 1999-07-15 구본준 기계 화학적 연마 방법 및 그 장치
KR19990001217A (ko) 1997-06-13 1999-01-15 윤종용 스탠바이 모드에서의 시스템 구동방법 및 장치
JP3723857B2 (ja) 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
KR100573704B1 (ko) 1998-12-02 2006-07-21 동아제약주식회사 인성장 호르몬의 안정화된 액상제제_
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
CN1284603C (zh) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 杂双官能聚乙二醇衍生物和它们的制备方法
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
AR040529A1 (es) * 2002-07-09 2005-04-13 Grandis Biotech Gmbh Formulaciones de hgh en alta concentracion que contienen 1,2-propilenglicol
CA2516314C (en) * 2003-03-18 2012-01-03 Ares Trading Sa Liquid growth hormone formulation and process of preparation thereof
KR100537260B1 (ko) 2003-09-03 2005-12-19 한미약품 주식회사 인간 성장 호르몬의 안정화된 액상 제제용 조성물
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ ノルディスク アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CA2540172A1 (en) * 2003-09-25 2005-03-31 Cangene Corporation Liquid human growth hormone formulation containing polyethylene glycol
DE10355189B4 (de) 2003-11-26 2015-04-30 Johnson & Johnson Medical Gmbh Verfahren zum Herstellen eines chirurgischen Implantats sowie chirurgisches Implantat
CA2551510C (en) 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation

Also Published As

Publication number Publication date
JP2009542629A (ja) 2009-12-03
WO2008004717A1 (en) 2008-01-10
LT2049148T (lt) 2016-11-25
EP2049148B1 (en) 2016-09-28
BRPI0621841A2 (pt) 2011-12-20
CN101505789A (zh) 2009-08-12
ES2605022T3 (es) 2017-03-10
EP2049148A1 (en) 2009-04-22
BRPI0621841B1 (pt) 2020-12-29
US20090298768A1 (en) 2009-12-03
HUE031329T2 (hu) 2017-07-28
EP2049148A4 (en) 2013-12-11
US8409586B2 (en) 2013-04-02
BRPI0621841B8 (pt) 2021-05-25
JP5180202B2 (ja) 2013-04-10
WO2008004717A9 (en) 2013-08-29
HK1216992A1 (zh) 2016-12-16

Similar Documents

Publication Publication Date Title
IL224225B (en) Liquid formulation of long-acting human growth hormone conjugate
ZA200904544B (en) Stable S-(+)-abscisic acid liquid and soluble granule formulations
EP2081502B8 (en) A medical device for attaching tissue to bone
EP1942981A4 (en) DISTRIBUTION OF MEDIUM TO TISSUE
PL1986606T3 (pl) Ciekłe formulacje zawierające fenylefrynę
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
EP1991284A4 (en) BIOIMPLANTS FOR USE IN TISSUE GROWTH
IL181348A0 (en) Liquid preparation of physiologically active peptide
EP2081607A4 (en) HYGIENE TOWEL WITH A MICROBIAL SUPPRESSIVE COMPOSITION
ZA200900125B (en) Liquid formulation of pyrethroids
PL1570866T3 (pl) Sposób dostarczania płynnego środka sterylizującego do sterylizatora
IL195034A0 (en) Liquid pharmaceutical formulation
GB0614586D0 (en) Pharmaceutical Formulation
IL209698A (en) Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox
HUE031329T2 (hu) Humán növekedési hormon stabil folyékony készítménye
PL2054028T3 (pl) Podskórne implanty uwalniające aktywny składnik przez przedłużony okres czasu
IL213711A (en) Nano-phenofibrate preparation
EP2073631A4 (en) AGROCHEMICAL FORMULATIONS OF LIQUID CRYSTALS
ZA200704926B (en) Modified human growth hormone
IL197033A0 (en) Single use self-disabling syringe
IL199756A0 (en) Medically active plaster
GB0813004D0 (en) Stable therapeutic formulation of human growth hormone
GB2451360B (en) Hormone replacement formulation
HK1136977A (en) Human growth hormone formulations
ZA200806439B (en) Stable dosage formulations of imidazolylalkyl-pyridines